Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    CRISPR Therapeutics AG

    NASDAQ: CRSP · Real-Time Price · USD
    41.66
    0.30 (0.73%)
    At close: Jun 16, 2025, 3:59 PM
    41.55
    -0.26%
    Pre-market: Jun 17, 2025, 04:52 AM EDT

    CRISPR Therapeutics Statistics

    Share Statistics

    CRISPR Therapeutics has 86.36M shares outstanding. The number of shares has increased by 1.01% in one year.

    Shares Outstanding

    n/a
    		 86.36M

    Shares Change (YoY)

    n/a
    		 1.01%

    Shares Change (QoQ)

    n/a
    		 0.49%

    Owned by Institutions (%)

    n/a
    		 76.5%

    Shares Floating

    n/a
    		 82.79M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,023

    FTD / Avg. Volume

    n/a
    		 0.05%

    Short Selling Information

    The latest short interest is 20.54M, so 23.78% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 20.54M

    Short % of Shares Out

    n/a
    		 23.78%

    Short % of Float

    n/a
    		 27.04%

    Short Ratio (days to cover)

    n/a
    		 10.62

    Valuation Ratios

    The PE ratio is -9.07 and the forward PE ratio is -9.27. CRISPR Therapeutics's PEG ratio is -0.07.

    PE Ratio

    n/a
    		 -9.07

    Forward PE

    n/a
    		 -9.27

    PS Ratio

    n/a
    		 94.87

    Forward PS

    n/a
    		 1.5

    PB Ratio

    n/a
    		 1.72

    P/FCF Ratio

    n/a
    		 -22.95

    PEG Ratio

    n/a
    		 -0.07
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for CRISPR Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 22.07, with a Debt / Equity ratio of 0.12.

    Current Ratio

    n/a
    		 22.07

    Quick Ratio

    n/a
    		 22.07

    Debt / Equity

    n/a
    		 0.12

    Debt / EBITDA

    n/a
    		 -0.5

    Debt / FCF

    n/a
    		 -1.55

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $89,058.52

    Profits Per Employee

    n/a
    		 $-931,938.93

    Employee Count

    n/a
    		 393

    Asset Turnover

    n/a
    		 0.02

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 3.59M

    Effective Tax Rate

    n/a
    		 -0.99%

    Stock Price Statistics

    The stock price has increased by -32.58% in the last 52 weeks. The beta is 1.74, so CRISPR Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.74

    52-Week Price Change

    n/a
    		 -32.58%

    50-Day Moving Average

    n/a
    		 37.69

    200-Day Moving Average

    n/a
    		 43.15

    Relative Strength Index (RSI)

    n/a
    		 60.94

    Average Volume (20 Days)

    n/a
    		 2,159,174

    Income Statement

    In the last 12 months, CRISPR Therapeutics had revenue of 35M and earned -366.25M in profits. Earnings per share was -4.34.

    Revenue

    n/a
    		 35M

    Gross Profit

    n/a
    		 -75.25M

    Operating Income

    n/a
    		 -466.57M

    Net Income

    n/a
    		 -366.25M

    EBITDA

    n/a
    		 -447.31M

    EBIT

    n/a
    		 -466.57M

    Earnings Per Share (EPS)

    n/a
    		 -4.34
    Full Income Statement

    Balance Sheet

    The company has 298.26M in cash and 223.69M in debt, giving a net cash position of 74.56M.

    Cash & Cash Equivalents

    n/a
    		 298.26M

    Total Debt

    n/a
    		 223.69M

    Net Cash

    n/a
    		 74.56M

    Retained Earnings

    n/a
    		 -1.37B

    Total Assets

    n/a
    		 2.17B

    Working Capital

    n/a
    		 1.75B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -142.77M and capital expenditures -1.9M, giving a free cash flow of -144.68M.

    Operating Cash Flow

    n/a
    		 -142.77M

    Capital Expenditures

    n/a
    		 -1.9M

    Free Cash Flow

    n/a
    		 -144.68M

    FCF Per Share

    n/a
    		 -1.71
    Full Cash Flow Statement

    Margins

    Gross margin is -215%, with operating and profit margins of -1333.05% and -1046.43%.

    Gross Margin

    n/a
    		 -215%

    Operating Margin

    n/a
    		 -1333.05%

    Pretax Margin

    n/a
    		 -1036.19%

    Profit Margin

    n/a
    		 -1046.43%

    EBITDA Margin

    n/a
    		 -1278.02%

    EBIT Margin

    n/a
    		 -1333.05%

    FCF Margin

    n/a
    		 -413.36%

    Dividends & Yields

    CRSP does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CRSP is $81.5, which is 95.6% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $81.5

    Price Target Difference

    n/a
    		 95.6%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 16
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 6.03

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist